Ving J. Lee, Ph.D.
Chief Scientific Officer
Dr. Lee received his BA and M.S.-Ph.D. from the Ohio State University and University of Illinois at Champaign-Urbana, respectively, and held postdoctoral fellowships at U. Illinois and Harvard University (NIH). He has held leadership and technical positions at Lederle Laboratories (Cyanamid), Microcide Pharmaceuticals, Iconix Pharmaceuticals (Iconix Biosciences), Anacor Pharmaceuticals, Limerick Biopharma, and CB Research and Development.
For most of his career, Dr. Lee has conducted multi-disciplinary programs with significant research components in discovery and preclinical technology. From 2002 to 2004, Dr. Lee was Chief Scientific Officer and Vice President, Discovery Research at Anacor Pharmaceuticals, Inc. where he directed research on boron-based therapeutics with support from a $22.6M Defense Advance Research Projects Agency (DARPA) contract. At Microcide, Dr. Lee held various positions including Vice President, Chemistry and Pre-clinical Research, Research Operations and Technology Assessment, and Senior Research Advisor responsible for research in beta-lactams for problematic gram-positive pathogens, uridyl-peptide antibiotics for problematic gram-negative pathogens, and inhibitors of bacterial efflux pumps. While at Lederle, he was responsible for the discovery of new anti-infectives, including the glycylcyclines, carbapenems, enhanced third-generation cephalosporins, beta-lactamase inhibitors, and new oncology agents.
Thematically, Dr. Lee’s research has encompassed i) eukaryotic systems biology considerations in the design of new molecular entities against prokaryotes based on natural product scaffolds, ii) understanding the function of eukaryotic transporters in drug deposition and metabolism, and iii) prokaryotic resistance factors. On the chemistry side, he has exploited i) the subtle reactivity found with certain natural products and ii) novel heterocycles with newer synthetic methods to create new molecular entities. This is exemplified by the incorporation of biological and metabolic considerations in the design of building blocks in the Adesis Catalog of Heterocyclic Intermediates initiative.
Dr. Lee is also advisor for several private and public biotech companies, venture capital firms, and co-founder of another biotech firm. He also serves on several National Institutes of Health study sections.
Andrew Cottone, Ph.D.
Dr. Cottone began his career in chemistry with CB Research and Development. This work focused on early stage process development and scale-up chemistry for the CB Catalog of Advanced Intermediates. Dr. Cottone then became one of the founders of Adesis, Inc. He holds an undergraduate degree in Chemistry and Biochemistry from LaSalle University, and a Ph.D. in Chemistry from the University of Florida, with a post-doctoral experience at the University of Delaware.
His doctoral research experience on substrate-metal complex interactions has provided insights into new reactions for preparative scale functionalization of azoles. He is the President at Adesis.
John Chiarello, Ph.D.
Director of Chemistry
Dr. Chiarello received his BS and Ph.D. from the College of New Jersey and the University of Pennsylvania, respectively. He has held positions of technical and managerial responsibilities in animal husbandry, drug discovery, and selective agricultural growth regulants, as well as insect control agents at American Cyanamid, Fort Dodge Animal Health (Wyeth), and FMC. Dr. Chiarello joined Adesis in 2006 and has held positions of increasing responsibilities including multi-project leadership in process and discovery projects.
Ms. Baylis-Powell has over 25 years of fiscal and contract management experience in the private and municipal sectors. She joined CB Research and Development, Inc. in 2001 and Adesis, Inc. in 2005. Ms. Baylis-Powell is responsible for the areas of contract management, finance, and operations. Her first career position was with a chemical manufacturer as a quality control chemist, supervising a 24-hour laboratory. Ms. Baylis-Powell holds a Bachelors of Science degree from the University of Maryland.
Senior Leadership Team
In addition to breadth of technical experience, a strength of Adesis’ senior management is their corporate tenure. Operationally, we grow our management team organically with personnel that fully understand the organization’s entrepreneurial, technical, and project management needs. The collective Adesis experience for the personnel shown is 60+ years.
Members (left to right) Ed Whittle Ph.D., Marion Earle Ph.D., Jack Church, Nathan Ross Ph.D., Douglas Williams Ph.D.
Explore the bioscience and chemical manufacturer professional associations that Adesis belongs to.
Here to Help.
Please let us know how we can assist you with your small molecular chemistry needs.